Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Entrada Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Entrada Therapeutics, Inc.’s stock price such as:

• Entrada Therapeutics, Inc.’s current stock price and volume
• Why Entrada Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TRDA from analysts
• TRDA’s stock price momentum as measured by its relative strength

About Entrada Therapeutics, Inc. (TRDA)

Before we jump into Entrada Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programmes for the potential treatment of neuromuscular and ocular diseases, among others. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Want to learn more about Entrada Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Entrada Therapeutics, Inc..

Entrada Therapeutics, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Entrada Therapeutics, Inc.’s stock price was $10.270.

Entrada Therapeutics, Inc. is up 1.88% from its previous closing price of $10.080.

During the last market session, Entrada Therapeutics, Inc.’s stock traded between $9.910 and $10.320. Currently, there are approximately 41.46 million shares outstanding for Entrada Therapeutics, Inc..

Entrada Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Entrada Therapeutics, Inc. Stock Price History

Entrada Therapeutics, Inc.’s (TRDA) price is currently up 47.77% so far this month.

During the month of November, Entrada Therapeutics, Inc.’s stock price has reached a high of $10.750 and a low of $6.090.

Over the last year, Entrada Therapeutics, Inc. has hit prices as high as $21.790 and as low as $4.930. Year to date, Entrada Therapeutics, Inc.’s stock is down 40.6%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Entrada Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there was 1 analyst who downgraded Entrada Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Entrada Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Entrada Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Entrada Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Entrada Therapeutics, Inc. (TRDA) by visiting AAII Stock Evaluator.

Relative Price Strength of Entrada Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Entrada Therapeutics, Inc. has a weighted four-quarter relative price strength of 9.96%, which translates to a Momentum Score of 83 and is considered to be Very Strong.

Want to learn more about how Entrada Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Entrada Therapeutics, Inc. Stock Price: Bottom Line

As of November 28, 2025, Entrada Therapeutics, Inc.’s stock price is $10.270, which is up 1.88% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Entrada Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.